A randomized phase II study of SM‐88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond
Abstract Background This trial explores SM‐88 used with methoxsalen, phenytoin, and sirolimus (MPS) in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC) Methods Forty‐nine patients were randomized to daily 460 or 920 mg oral SM‐88 with MPS (SM‐88 Regimen). The primary endpoint was objec...
Main Authors: | Marcus S. Noel, Semmie Kim, Marion L. Hartley, Steve Wong, Vincent J. Picozzi, Harry Staszewski, Dae Won Kim, Jan M. Van Tornout, Philip Agop Philip, Vincent Chung, Allyson J. Ocean, Andrea Wang‐Gillam |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-11-01
|
Series: | Cancer Medicine |
Online Access: | https://doi.org/10.1002/cam4.4768 |
Similar Items
-
Interaction of azapropazone with phenytoin.
by: Geaney, D, et al.
Published: (1982) -
Phenytoin-Induced Gingival Enlargement
by: Satvinder Singh Bakshi
Published: (2019-05-01) -
Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020-10-01) -
Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations
by: Krasowski Matthew D, et al.
Published: (2012-02-01) -
ABC of monitoring drug therapy. Phenytoin.
by: Aronson, J, et al.
Published: (1992)